These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
6. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer. Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737 [TBL] [Abstract][Full Text] [Related]
7. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892 [TBL] [Abstract][Full Text] [Related]
8. Targeting the androgen receptor signaling pathway in advanced prostate cancer. Chung C; Abboud K Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118 [TBL] [Abstract][Full Text] [Related]
9. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741 [TBL] [Abstract][Full Text] [Related]
10. Pioneer of prostate cancer: past, present and the future of FOXA1. Teng M; Zhou S; Cai C; Lupien M; He HH Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061 [TBL] [Abstract][Full Text] [Related]
11. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials. Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209 [TBL] [Abstract][Full Text] [Related]
13. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Jin HJ; Zhao JC; Wu L; Kim J; Yu J Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621 [TBL] [Abstract][Full Text] [Related]
14. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. Hwang JH; Arafeh R; Seo JH; Baca SC; Ludwig M; Arnoff TE; Sawyer L; Richter C; Tape S; Bergom HE; McSweeney S; Rennhack JP; Klingenberg SA; Cheung ATM; Kwon J; So J; Kregel S; Van Allen EM; Drake JM; Freedman ML; Hahn WC Elife; 2022 May; 11():. PubMed ID: 35550030 [TBL] [Abstract][Full Text] [Related]
15. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096 [TBL] [Abstract][Full Text] [Related]
16. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975 [TBL] [Abstract][Full Text] [Related]
17. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115 [TBL] [Abstract][Full Text] [Related]
18. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. Fujimoto N J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726 [TBL] [Abstract][Full Text] [Related]
19. FOXA1: a transcription factor with parallel functions in development and cancer. Bernardo GM; Keri RA Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363 [TBL] [Abstract][Full Text] [Related]
20. Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. Zhou J; Wang Y; Wu D; Wang S; Chen Z; Xiang S; Chan FL Oncogene; 2021 Apr; 40(15):2625-2634. PubMed ID: 33750894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]